Perfluorodecalin allows resuspension and prevents sediment solidification of extended-release drug formulations in primary packaging.

IF 5.7 3区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Drug Delivery and Translational Research Pub Date : 2025-01-01 Epub Date: 2024-05-04 DOI:10.1007/s13346-024-01598-7

Daniel Primavessy, Sarah Büttner, Sigrid Saaler-Reinhardt

引用次数: 0

Abstract

In this technical note we show with two simple experiments how Perfluorodecalin (PFD), an injectable perfluorocarbon, can be used as an agent for resuspending microparticulate suspensions in primary packaging containers for injection. Furthermore, we explain how this can be a substantial improvement regarding patient compliance in comparison to the commonly used gas headspace for resuspension. Our experiments are conducted with poly(lactic-co-glycolic acid) particles (often used in extended-release pharmaceutical formulations for injection) and in primary packaging that is commonly used in injection devices (glass cartridges). The results show that our method is feasible for resuspension and moreover even sediment solidification/caking is reduced. The differences between the two datasets collected are statistically significant with p < 0.01 in both cases.

Abstract Image

查看原文本刊更多论文

全氟萘烷可以使缓释药物制剂在初级包装中重新悬浮并防止沉淀凝固。

在本技术说明中，我们通过两个简单的实验展示了全氟萘烷（PFD）--一种可注射的全氟碳化合物--如何用作重悬注射用初级包装容器中微粒悬浮液的药剂。此外，我们还解释了与常用的气体顶空再悬浮法相比，这种方法如何大大提高了患者的依从性。我们使用聚（乳酸-共聚-乙醇酸）颗粒（常用于注射用缓释药物制剂）和注射设备中常用的初级包装（玻璃筒）进行了实验。结果表明，我们的方法适用于再悬浮，而且甚至可以减少沉积物的凝固/结块。收集到的两个数据集之间的差异具有统计学意义（P

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Delivery and Translational Research MEDICINE, RESEARCH & EXPERIMENTALPHARMACOL-PHARMACOLOGY & PHARMACY

CiteScore

11.70

自引率

1.90%

发文量

160

期刊介绍： The journal provides a unique forum for scientific publication of high-quality research that is exclusively focused on translational aspects of drug delivery. Rationally developed, effective delivery systems can potentially affect clinical outcome in different disease conditions. Research focused on the following areas of translational drug delivery research will be considered for publication in the journal. Designing and developing novel drug delivery systems, with a focus on their application to disease conditions; Preclinical and clinical data related to drug delivery systems; Drug distribution, pharmacokinetics, clearance, with drug delivery systems as compared to traditional dosing to demonstrate beneficial outcomes Short-term and long-term biocompatibility of drug delivery systems, host response; Biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering; Image-guided drug therapy, Nanomedicine; Devices for drug delivery and drug/device combination products. In addition to original full-length papers, communications, and reviews, the journal includes editorials, reports of future meetings, research highlights, and announcements pertaining to the activities of the Controlled Release Society.